. 2015 Mar 10;3:e835. doi: 10.7717/peerj.835

Table 2. Patient characteristics (patients in studies that reported outcomes of interest).

Characteristics of patients in the included studies.

Study, year (reference)	Mean age (yrs) ± SD	Excluded patients		Follow-up duration	Patients lost to follow-up	Patients (n): LMWH/UH	Frequency and duration of dialysis	Type of LMWH	Mean LMWH dose	Mean UFH dose
		Other anticoagulants	Previous bleeding
Borm et al., 1986	58.6	No	NS	NS	0/0	10	2-3/wk, 4 h	Dalteparin	(B) 18 IU/kg; (I) 9 IU/kg/h	(B) 36 IU/kg; (I) 18 IU/kg/h
Saltissi et al., 1999	68.5	No	No	24 weeks	5	36	3–4/wk, 3–5 h	Enoxaparin	(B) 1 mg/kg; (I) 0.69 mg/kg/h	(B) 50 IU/kg; (I) 1,000 IU/h
Lord et al., 2002	66.6 ± 14.8	No	No	8 weeks	2	32	3/wk, 3.5–4 h	Tinzaparin	4318 IU	(B) 50–75 IU/kg; (I) NS
Schrader et al., 1988	54 ± 15.2 (LMWH), 51.6 ± 17.9 (UFH)	No	NS	12 months	8	70 (35/35)	NS, 4.5–5 h	Dalteparin	(B) 34 IU/kg; (I) 12 IU/kg/h	(B) 62 IU/kg; (I) 17 IU/kg
Harenberg et al., 1995	53.4 ± 19.9 (LMWH), 59.1 ± 15.72 (UFH)	NS	NS	NS	NS	20 (10/10)	3–4 h, 4/wk	Dalteparin	(B) 1750 IU (I) 26.4 IU/kg	(B) 2650 IU; 36.6 IU infusion
Verzan et al., 2004	NS	NS	NS	NS	NS	66	3/wk, 4–5 h/session	Tinzaparin	40 IU/kg	Mean dose 6262 2300IU/session
Mahmood et al., 2010	52.1 ± 17.2	NS	NS	NS	NS	20	3/wk, 4–5 h/session	Tinzaparin	(B) 34 IU/kg; (I) 12 IU/kg/h	(B) 62 IU/kg; (I) 17 IU/kg
Gritters et al., 2006	55.2 ± 11.7	NS	NS	NS	NS	8	3/wk, 4–5 h/session	Dalteparin	NS	(B) 62 IU/kg; (I) 17 IU/kg
Elisaf et al., 1997	57.1 ± 12.3	NS	NS	NS	NS	36	NS	Tinzaparin	(B) 34 IU/kg; (I) 12 IU/kg/h	NS

Notes.